Lercanidipine Hydrochloride Pinewood Laboratories

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Hydrochloride Pinewood Laboratories, is a calcium channel blocker presented as an oral dosage form for oral use. It is prescribed to lower elevated blood pressure in adults with hypertension. It belongs to the dihydropyridine subclass and provides once‑daily dosing convenience.

GNH USA supplies Lercanidipine Hydrochloride Pinewood Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers regulatory support for importation.

Lercanidipine Hydrochloride is used to manage hypertension, a condition characterized by chronically elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Isolated systolic hypertension: lowers elevated systolic pressure, improving arterial compliance. - Essential hypertension: provides sustained blood pressure control in primary hypertension.

Lercanidipine Hydrochloride may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation with reddening of the skin. - Peripheral edema: swelling of ankles or lower legs. - Dizziness: sensation of light‑headedness, especially after standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of face, lips, or throat that may compromise airway.

When prescribing Lercanidipine Hydrochloride, clinicians should consider several safety measures.

- Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction. - Elderly patients: start at lower doses and monitor for dizziness. - Concomitant antihypertensives: adjust therapy to prevent additive effects. - Discontinuation: avoid abrupt cessation; taper if necessary. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with other medicines, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Other calcium channel blockers: additive vasodilatory effect can cause hypotension. - Grapefruit juice: enhances drug exposure through CYP3A4 inhibition.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response. - Beta‑blockers: monitor for excessive blood pressure lowering. - Diuretics: assess electrolyte balance and blood pressure changes.